Skip to search.

Breaking News Visit Yahoo! News for the latest.

×Close this window

 Dow Down0.52% Nasdaq Down1.11%

Ampio Pharmaceuticals, Inc. (AMPE)

-NasdaqCM

4.69 Down 0.13(2.70%) 4:00PM EDT|After Hours : 4.69 0.00 (0.00%) 4:31PM EDT

Add to Portfolio
ProfileGet Profile for:
Ampio Pharmaceuticals, Inc.
5445 DTC Parkway
Suite 925
Greenwood Village, CO 80111
United States - Map
Phone: 720-437-6500
Fax: 720-437-6501
Website: http://www.ampiopharma.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Drug Manufacturers - Major
Full Time Employees:13

Business Summary 

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, together with its subsidiaries, engages in the discovery and development of pharmaceutical drugs and diagnostic products to identify, treat, and prevent metabolic disorders, eye diseases, kidney diseases, acute and chronic inflammation diseases, and male sexual dysfunction. Its products include Ampion, a non-steroidal anti-inflammatory biologic to treat inflammatory conditions and autoimmune diseases; Optina, an orally administered danazol for the treatment of diabetic macular edema; Vasaloc for the treatment of diabetic nephropathy; and Zertane, an oral drug for treating male sexual dysfunction to premature ejaculation, which is under Phase III clinical trial. The company is also developing a handheld oxidation-reduction potential diagnostic device for use at home or in healthcare facilities that will measure the oxidants/antioxidant balances in human blood and plasma; and methylphenidate derivatives for cancer, which are in pre-clinical development. Ampio Pharmaceuticals, Inc. is headquartered in Greenwood Village, Colorado.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Ampio Pharmaceuticals, Inc.

Corporate Governance 
Ampio Pharmaceuticals, Inc.’s ISS Governance QuickScore as of May 1, 2013 is 8. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 4; Compensation: 8.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Mr. Michael Macaluso , 61
Founder, Chairman and Chief Exec. Officer
238.00K0.00
Mr. Mark D. McGregor , 71
Chief Financial Officer, Principal Accounting Officer and Corp. Sec.
155.00K0.00
Mr. Joshua R. Disbrow , 37
Chief Operating Officer
11.00K0.00
Dr. David Bar-Or M.D. , 64
Chief Scientific Officer and Director
405.00K0.00
Dr. Vaughan L. Clift M.D., 52
Chief Regulatory Affairs Officer
255.00K0.00
Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders